循环肿瘤细胞在肝细胞癌诊疗中的应用及展望

Circulating tumor cells in diagnosis and treatment of hepatocellular carcinoma:application and prospect

肝细胞癌(HCC)是一种高度恶性肿瘤,是癌症相关死亡的第三大原因。血清甲胎蛋白和影像学检查是HCC早期诊治和疗效动态监测最常用的手段。然而这些手段的准确性有限,不能明确反映肿瘤的潜在生物学特性。因此,开发能够更准确、全面地反映HCC生物学特性的新型肿瘤标志物具有潜在的临床应用价值。循环肿瘤细胞(CTC)是来源于原发肿瘤或转移灶并存在于血液循环中的癌细胞,其提供了关于肿瘤进展和转移的重要信息,是早期诊断和复发、转移、预后评估的良好候选指标,甚至是HCC潜在的治疗靶点。本文讨论了CTC在HCC患者临床全疗程管理中的应用及其局限性和未来研究方向。

Hepatocellular carcinoma(HCC)is a highly malignant tumor and the third cause of cancer-related death.Serumα-fetoprotein and imaging examination are the most commonly used tests for early diagnosis,treatment and dynamic efficacy monitoring of HCC.However,the accuracy of these approaches is limited and can not clearly reflect the underlying biological characteristics of the tumor.Therefore,novel HCC tumor markers that are more accurate and can comprehensively reflect the biological characteristics of the tumor have potential clinical application value.Circulating tumor cell(CTC),as a kind of cancer cells derived from primary tumors or metastases,provides important information about tumor progression and metastasis,and is good candidate for early diagnosis and evaluation of metastasis,recurrence,and prognosis,and even potential therapeutic target for HCC.This article discusses the application of CTC in the whole clinical course management of HCC patients,as well as its limitations and future research direction.